MHRA Freedom of Information Act (FOIA) request Disclosure Log index

This document contains reference details for all FOIA requests which have been answered in full or in part, or for which the agency held no information.

It is a fully searchable PDF which will produce a list of all requests containing the chosen search term.

If you wish to see the original request and subsequent agency reply, please send an email headed “Disclosure Log request” to:

FOI_policy@mhra.gsi.gov.uk

As long as it is headed correctly it will not be treated as a new FOIA request. The identity of the original requester will be redacted.

Updated: 02 August 2018

FOI no	*Subject*	*Date reply sent*	*Result of request*
18/001	Information on HPV vaccination between 1st October 2017 and 31st December 2017; Drug name (please specify Gardasil or Gardasil 9) age, gender, reaction & outcome	30/01/2018	Disclosed in full
18/002	Copies of the Clinical and Non-Clinical Overviews for Sennosides 7.5 mg tablets PL 33831/0029	19/01/2018	Disclosed in part
18/003	Azzalure and Dysport	25/01/2018	Disclosed in full
18/004	Applications made by overseas MF for Liothyronine Sodium 20mcg tablets	29/01/2018	Disclosed in part
18/005	Requesting details of the controlled distribution system(s) in place for each company marketing bosentan.	31/01/2018	Disclosed in part
18/006	FOI requests 'answered in part' from 2017 onwards. In particular, the sections used for refusal (as is supplied for the requests not answered).	15/01/2018	Disclosed in full
18/007	Full breakdown of expenditure by staff in your department on the Government Procurement Card, or any other credit card paid out public funds for a)2016/17 and b)2017/18 to date	06/02/2018	Disclosed in part
18/008	Ashfield Healthcare	02/02/2018	Disclosed in full
18/009	Request report (Petersen J.. Wise, L. Prescribing trends of bisphosphonates in general practice, UK 1995-2008. Pharmacoepidemiology and Drug Safety. '19. 'S315).	11/01/2018	Disclosed in full
18/010	Request MHRA to share RMP summary or summary of safety concerns for Injection.	10/01/2018	Not held
18/013	Copies of all comparable data regarding the use of Electroconvulsive Therapy (ECT) as a treatment method in all of the NHS Mental Health trusts in England from 1948 to date.	22/01/2018	Not held
18/014	Confirm the serious adverse side effects (also name of vaccine) from child hood vaccines in the UK from period of 2003 to present day 2018	07/02/2018	Disclosed in full
18/015	Request assessment of the dossier for Alateris 625 mg tablets, Alka-Seltzer XS, Quinine Sulfate 300 mg tablets, Gregovite Ca tablets, Forceval capsules, Synthamin 14, 8.5 Amino Acid Intravenous Infusion.	05/02/2018	Disclosed in part
18/016	Prozac PILs	07/02/2018	Disclosed in full
18/018	Unicough 14mg/ 135 mg/ 1.1 mg/ 5 ml Oral Solution variation registration date 23.04/2015	21/02/2018	Disclosed in part
18/020	Request Public Assessemnt reports for Calpol	02/02/2018	Disclosed in full
18/021	Request about flights your organisation has paid for since 1 January 2015.	06/02/2018	Disclosed in part
18/025	Volume of applications you receive for new drug approvals/licences to market drugs, by origin, preferably by year, over the last 10 years.	09/02/2018	Disclosed in full
18/027	Pharmacovigilance inspection reports from November 2017 and December 2017.	09/02/2018	Disclosed in full
18/028	Request for information on PEEK implant for shoulder surgery	15/02/2018	Disclosed in full
18/029	Request for a breakdown of all the alleged Co-Cyprindiol side effects reported to you under the yellow card scheme between 1.7.16 and 30.6.17.	14/02/2018	Disclosed in full

FOI no	*Subject*	*Date reply sent*	*Result of request*
18/030	Request information your organisation hold that pertains to, or implicates, any Freemason to any alleged crime.	09/02/2018	Not held
18/031	Request paperwork that was sent from Scherings to the Committee On Safety Of Medicines to confirm the change of use of Primodos in 1970 and why had the change been made?	19/02/2018	Not held
18/032	Request for Risk Management Plan submitted by Medice for *Amfexa 10mg and 20mg Tablets* (**PL 11243/023-0024**)	13/02/2018	Disclosed in part
18/033	Would you kindly confirm if you are aware of any regulatory or compliance matters Emcure have been involved in either with yourselves or any other relevant drug authoritiesn such as the FDA	19/02/2018	Disclosed in full
18/034	Energy Suppliers	19/02/2018	Disclosed in full
18/036	Social media account and expenditure	22/02/2018	Disclosed in full
18/037	Request the latest inspection reports for Martindale and Ethypharm.	19/02/2018	Disclosed in part
18/039	Did the MHRA give approval for the use of G-CSF, EPO and research grade TGF-3 beta for the intervention performed under compassionate use on the child patient, Ciaran Lynch? (Lancet 2012).	15/02/2018	Disclosed in full
18/040	Investigations and research program methods in progress into systemic neurological and any other damage caused by human in vivo chrome-cobalt alloy hip and other implant components.	23/02/2018	Not held
18/042	Update on metal on metal implant	23/02/2018	Disclosed in part
18/043	Request Public Assessment Report for ISOSORBIDE DINITRATE 0.1% (PL 13079/0003).	09/02/2018	Disclosed in full
18/044	Details on the number of adverse incident reports received after hernia mesh in both men and women from 2006 to date.	23/02/2018	Disclosed in full
18/045	Latest M & A Pharmachem Inspection report	14/03/2018	Disclosed in part
18/047	Inspection report for Manx Pharma WDA(H) 15833	01/03/2018	Disclosed in part
18/048	Inspection report for Universal Marine Medical Supply WDA(H) 43439	01/03/2018	Disclosed in part
18/049	Inspection report for ANP Pharma WDA(H) 36080	01/03/2018	Disclosed in part
18/050	Inspection report for Hutton & Co Ship Chandlers WDA(H) 35764	01/03/2018	Disclosed in part
18/051	Inspection report for Kays Medical WDA(H) 3485	01/03/2018	Disclosed in part
18/052	Cradelcrest Ltd (T/A Wells Offshore) WDA(H) 8431	01/03/2018	Disclosed in part
18/053	Infrmation on Ropinirole side effects	23/02/2018	Disclosed in full

FOI no	Subject	Date reply sent	Result of request
18/054	Risk Management plans for 1) Mucodyne 375mg capsules, Hard 2) Carbocisteine capsules 375mg 3) Carbocisteine chanelle medical capsules 375mg 4) Carbocisteine capsules 375mg	23/02/2018	Disclosed in part
18/056	List of all reported adverse events taking into account the longest period of time for Dysport and Azzalure	05/03/2018	Disclosed in full
18/057	Why are vaccine DAP's are not readily accessible alongside all the other pharmaceutical products available on line.	19/02/2018	Disclosed in full
18/058	Numbers of failure(s) and patient numbers affected by a failure in formalin based fixatives.	22/02/2018	Disclosed in full
18/059	Inspection reports for all MHRA pharmacovigilance inspections of Cipla?	07/03/2018	Disclosed in part
18/060	Lariam (mefloquine) Roche Drug Safety Reports for 01 Jan 1999 - 31 Dec 1999.	06/03/2018	Disclosed in part
18/062	Provide all copies of all drug safety updates relating to Gadolinium contract agents from period from 1 January 2012 to present	05/03/2018	Disclosed in full
18/063	Please provide a list for all successful requests, or those disclosed in part from September 2017 until the end of the year	08/03/2018	Disclosed in full
18/064	Information about medicines exported to Libya.	20/03/2018	Disclosed in part
18/065	Pharmacovigilance inspection reports from November 2016 and December 2016.	08/03/2018	Disclosed in part
18/066	Levothryroxine information	06/03/2018	Disclosed in part
18/068	Information about whether the Liothyronine manufacturing process, plant and update the analytical tests was modernised in accordance with new MHRA standards.	07/03/2018	Disclosed in part
18/069	Information about studies on histomorphological changes in ovaries, ovulation and ovulatory capacity for GARDASIL and GARDASIL 9	26/02/2018	Disclosed in full
18/070	What information and processes did the MHRA use to compare and benchmark their revised manufacturing standards for Liothyronine against those of other regulators, e.g. those in Europe?	07/03/2018	Disclosed in part
18/071	What specific documents (or information) did the MHRA use to set their revised manufacturing standard requirements on Liothyronine?	07/03/2018	Disclosed in part
18/073	Public assessment reports for glycopyrronium bromide (1mg/5ml), chloral hydrate (5mg/5ml, 100mg/5ml) and levothyroxine	21/02/2018	Disclosed in full
18/074	Request risk management plans for Voltarol 1.16% Emulgel (MAH: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited; PL 44673/0157). Ibuleve gel (MAH: Diomed Developments Limited; PL 00173/0060). Prenoxad 1mg/ml Solution for Injection in a pre-filled syringe (MAH: Aurum Pharmaceuticals Ltd; PL 12064/0125)	23/02/2018	Disclosed in part
18/075	Request information on adverse events reported for implantable mesh devices between 2006-present date. Mesh for SUI, Mesh for pelvic organ prolapse, Abdominal/Hernia Mesh & Mesh for other areas.	13/03/2018	Disclosed in full
18/077	What applications have been made by Indivior and Braeburn to licence drugs to treat addiction	15/02/2018	Disclosed in part
18/078	Breakdown of expenditure by staff in your department on the Government Procurement Card or any other credit card paid out using public funds, in the financial year **2017/18** to date.	13/03/2018	Disclosed in part

FOI no	*Subject*	*Date reply sent*	*Result of request*
18/079	Request the latest annual report from the MHRA to the JCVI vaccine-associated suspected adverse reactions reported via the yellow card scheme	21/02/2018	Disclosed in full
18/081	Breakdown of expenses for your board members for 2017/18 and 2016/17	15/03/2018	Disclosed in full
18/082	A copy of the GORMET study report, which covers safety aspects of two of metoclopramide and domperidone.	16/02/2018	Disclosed in full
18/083	Information about whether MHRA has a performance-based bonus scheme for its employees.	13/03/2018	Disclosed in full
18/085	DAIICHI SANKYO UK LTD - copies of educational material	09/03/2018	Not held
18/086	Copies of the following educational materials. STRATTERA Physician's Guide including additional tools. Checklist for actions to take before prescribing/dispensing or administering atomoxetine	09/03/2018	Disclosed in part
18/087	do MHRA have any information/knowledge/concerns past or present regarding the Boston Scientific Advantage Fit (mesh)	13/03/2018	Disclosed in part
18/088	We kindly request MHRA to provide us access to the RMP/ RMP summary for Neupogen	09/03/2018	Disclosed in part
18/089	Yellow card reports for Raltegravir	21/03/2018	Disclosed in full
18/091	Information about prosecutions by MHRA.	20/03/2018	Disclosed in part
18/092	GMP inspection report for Invidor UK Ltd	20/03/2018	Disclosed in part
18/093	Official policy on use of organisational Facebook or Twitter Accounts	22/03/2018	Disclosed in full
18/094	RMP Viagra Connect 50mg film coated tablets – PL 00165/0392; UK/H/6416/001/DC	23/03/2018	Disclosed in part
18/096	Information on Lariam	22/03/2018	Disclosed in full
18/098	Request for the most recent 300 EMA inspection post inspection letters for GMP/GDP inspections	27/03/2018	Disclosed in part
18/101	Information on falsified or substandard antimicrobials recorded on the Global Surveillance and Monitoring System for SF medical products database	27/03/2018	Not held
18/102	UKPAR for Sulfasalazine 500mg tablets	01/03/2018	Disclosed in full
18/103	PAR for Dexamethasone sodium phosphate Strides 4 mg/ml solution for injection and Dexamethasone phosphate 4 mg/ml Solution for Injection or Infusion	13/03/2018	Disclosed in full
18/105	RMP or the table of safety concerns of Ibuprofen/Paracetamol tablets	23/03/2018	Disclosed in part
18/106	Information whether any companies test people's blood/serum sample after BoNT/A or BoNT/B injection?	28/03/2018	Disclosed in full
FOI 18/107	Copy of Change of Ownership application details made between ACTIVASE PHARMACEUTICALS (THR28444/0139) to BELL SONS & CO (DRUGGISTS) LIMITED (THR03105/0002)	04/04/2018	Disclosed in part
FOI 18/108	Request details of all trial results with **all vaccines** that have been done against placebo & not against other forms of vaccine.	29/03/2018	Disclosed in part
FOI 18/109	GMP inspection report for Capsugel/ Lonza (previously Encap Drug Delivery) Units 4,5 & 6 Oakbank Parkway Livingston West Lothian EH53 0TH	12/04/2018	Disclosed in part
18/110	A list of meetings held between the MHRA and Cannabis Trades Association (CTA UK) in the last 24 months.	12/04/2018	Disclosed in full

FOI no	*Subject*	*Date reply sent*	*Result of request*
18/111	Information on NHS Business Services Authority unique data for patients on benzodiazepines, antidepressants and opioid containing medicines given in answer to a Parliamentary Question.	03/04/2018	Not held
18/112	Request for 16th October 2015 MHRA Minutes, standing item 10.1, Human Papillomavirus (HPV) Vaccine - currently redacted under FOIA section 35, Formulation of Government Policy.	22/03/2018	Disclosed in full
18/113	Information about spontaneous suspected Adverse Drug Reaction (ADR) reports for HPV vaccinations received since 2008.	04/04/2018	Disclosed in full
18/114	Information about numbers of complaints about slimming aids.	05/04/2018	Disclosed in part
18/115	Please can you confirm that it is a legal requirement for manufacturers to supply a PSUR to the regulatory authority	04/04/2018	Not held
18/117	Report on AMS Elevates devices implanted at the SEHSCT hospitals between 2012(2), 2013 (1) and 2014 (2).	15/03/2018	Disclosed in part
18/118	Information on when the licences for Paradote Tablets were withdrawn or cancelled; whether the withdrawal / cancellation was at the request of the MA holder or the Licensing Authority ((MHRA); the reason for the withdrawal or cancellation of the MAs.	09/04/2018	Disclosed in full
18/119	Eskazole clinical study report request	09/04/2018	Not held
18/121	Please may I request the figures of all spontaneous ADRs received from 2011-present day, and also reporter type	13/04/2018	Disclosed in full
18/122	I would like to request a copy of the risk management plan for Viagra Connect (UK/H/6416/001/DC).	11/04/2008	Disclosed in part
18/123	HMR enforcement actions	17/04/2018	Disclosed in full
18/124	Information that held about lenalidomide	10/04/2018	Disclosed in part
18/125	PAR Paracetamol oral suspension	19/03/2018	Disclosed in full
18/126	Adverse incident reports on electrical/battery operated hoists	17/04/2018	Disclosed in part
18/127	Please send me the latest PV and GCP Inspection reports for Celgene UK	20/04/2018	Disclosed in part
18/129	A copy of the Public Assessment Reports (UKPARs) for Residerm 1% gel & Zindaclin 1% gel	22/03/2018	Disclosed in full
18/130	Please state the number of abortion pills that had been bought online which were seized by the MHRA for each of the following years:2014-18	19/04/2018	Disclosed in full
18/132	Courier service procurement information	28/03/2018	Disclosed in full
18/133	A copy of MHRA's assessment of the "NHS 111" app powered by Babylon Health	27/03/2018	Disclosed in full
18/134	ADR information for venom therapy	24/04/2018	Disclosed in full
18/135	what year Cycloporin was licensed for clinical use in the UK (the US FDA licensed it in 1983)	29/03/2018	Disclosed in full
18/136	Use of animals in research by MHRA	25/04/2018	Disclosed in **part**
18/137	Information on clinical trials on Insulin and High Throughput Screening	10/04/2018	Disclosed in full

FOI no	*Subject*	*Date reply sent*	*Result of request*
18/138	November 2017 GSK Pharmaceuticals, Vaccines and Consumer Healthcare pharmacovigilance inspection report.	23/04/2018	Disclosed in part
18/139	PAR Hydroxocobalamin injection	28/03/2018	Disclosed in full
18/140	PAR diazepam oral solution	29/03/2018	Disclosed in full
18/141	What pre and post market checks are carried out for pelvic mesh	23/04/2018	Disclosed in full
18/142	Audits or investigations already undertaken or pending which relate to the Pregnancy Prevention Programme for lenalidomide (Revlimid®), manufactured by Celgene	11/04/2018	Disclosed in part
18/143	Licensing information for Thiotepa	26/04/2018	Disclosed in part
18/144	Procurement contract info for MHRA	25/04/2018	Disclosed in full
18/145	SOP for approving marketing authorisations	24/04/2018	Disclosed in part
18/148	Info about feasibility studies have been done by MHRA in collaboration with Public Health England (PHE) or other government or other agency to explore the possibility of undertaking an epidemiological study of the alleged association between HPV vaccine and POTS and CRPS.	27/04/2018	Disclosed in part
18/150	PAR for Clotrimazole 200mg vaginal tablets	29/03/2018	Disclosed in full
18/158	Yellowcard data for medicines and devices	20/04/2018	Disclosed in full